Cargando…

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”

Detalles Bibliográficos
Autores principales:	Papamichos, Spyros I., Jungbauer, Christof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553948/ https://www.ncbi.nlm.nih.gov/pubmed/32704175 http://dx.doi.org/10.1038/s41416-020-1005-5

Ejemplares similares

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020)

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
por: Amrein, Lilian, et al.
Publicado: (2009)

Expert consensus on the management of chronic lymphocytic leukaemia in Asia
por: Tse, Eric, et al.
Publicado: (2023)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
por: Wierda, William G., et al.
Publicado: (2018)

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells
por: Hofbauer, Sebastian W., et al.
Publicado: (2015)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
por: Christoforidou, Anna, et al.
Publicado: (2018)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Inactivation of Prostaglandin E(2) as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia
por: Allain, Eric P., et al.
Publicado: (2019)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015)

The t(11;14)(q13;q32)/CCND1–IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course
por: Liu, Ying, et al.
Publicado: (2019)

Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?
por: Yang, Shenmiao, et al.
Publicado: (2021)

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
por: Fatima, Narjis, et al.
Publicado: (2020)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

Lymphocytic lymphoma/B-chronic lymphocytic leukaemia--an immunohistopathological study of peripheral B lymphocyte neoplasia.
por: Swerdlow, S. H., et al.
Publicado: (1984)

Comment on the risk of hepatocellular carcinoma with chronic hepatitis B infection in Sweden
por: Singh, Satender Pal, et al.
Publicado: (2022)

Chronic Lymphocytic Leukaemia—New Drugs and Management: CME Lecture
por: Hamblin, Terry J
Publicado: (1995)

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia
por: Murali, Aarya, et al.
Publicado: (2021)

Microsatellite instability in patients with chronic B-cell lymphocytic leukaemia
por: Niv, E, et al.
Publicado: (2005)

Molecular characterization and clonal evolution in Richter transformation: Insights from a case of plasmablastic lymphoma (RT‐PBL) arising from chronic lymphocytic leukaemia (CLL) and review of the literature
por: Ramsey, Megan C., et al.
Publicado: (2023)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Red wine and component flavonoids inhibit UGT2B17 in vitro
por: Jenkinson, Carl, et al.
Publicado: (2012)

Impact of UGT2B17 gene deletion on the steroid profile of an athlete
por: Martín‐Escudero, Pilar, et al.
Publicado: (2015)

Response to letter to the editor PD‐17‐0390, a comment on “Comparing methods for fetal fraction determination and quality control of NIPT samples”
por: van Beek, Daphne M., et al.
Publicado: (2017)

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
por: Koehler, Philipp, et al.
Publicado: (2012)

Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia
por: Rogne, Marie, et al.
Publicado: (2018)

Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma
por: Mafune, Aki, et al.
Publicado: (2015)

Response to comment by Moxon et al.
por: Thompson, Dawn, et al.
Publicado: (2018)

Response to comment by Guerra et al.
por: Yang, Xinyue, et al.
Publicado: (2018)

Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
por: Paneesha, S., et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib
por: Choi, Jung Hye, et al.
Publicado: (2023)

A case of leukaemia cutis in a dog with T‐cell chronic lymphocytic leukaemia
por: Bae, Hyeona, et al.
Publicado: (2022)

Ribosomal RNA Synthesis in Chronic Lymphocytic Leukaemia
por: Billington, R. W., et al.
Publicado: (1974)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children
por: Du, Zhongliang, et al.
Publicado: (2016)

UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-Analysis
por: Kpoghomou, Marce-Amara, et al.
Publicado: (2013)

Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia
por: Sandoval, Juan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qvrlcc1u6bo6p4ldlq8vusol37